

# R

\*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Rabbit anti-human thymocyte immunoglobulin (Thymoglobuline®) (489/08)	Immunosuppression in solid organ transplantation	Not recommended	<a href="#">82</a>	Aug/Sept 2008
Rabeprazole (Pariet®)	Symptomatic GORD without oesophagitis – on-demand therapy		<a href="#">47</a> <a href="#">44</a>	2004
Rabeprazole (Pariet®)	Zollinger-Ellison syndrome	Not recommended	<a href="#">55</a>	2006
Racecadotril (Hidrasec Infants®, Hidrasec Children®) (818/12)	Acute diarrhoea in infants	Not recommended	<a href="#">140</a> <a href="#">123</a>	Jul/Aug 2014 Jan 2013
Racecadotril (Hidrasec®) (832/12)	Acute diarrhoea in adults	Not recommended	<a href="#">123</a>	Jan 2013
Radium-223 dichloride (Xofigo®) (1077/15)	For the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.	Non-formulary - absence of Clinician demand	<a href="#">152</a>	Nov/Dec 2015
Raltegravir 100mg granules for oral suspension (Isentress®) SMC2101	In combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.	Not available as not recommended for use in NHS Scotland	<a href="#">170</a>	Sep 2018
Raltegravir 600mg film-coated tablets (Isentress®) SMC No 1280/17	In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and paediatric patients weighing at least 40kg.	Available in line with National Guidance	<a href="#">165</a>	Jan 2018

Raltegravir (Isentress®) for adults and children (1102/15)	For treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of 4 weeks	Formulary - Hospital Use (HIV and Paediatrics)	<a href="#">152</a>	Nov/Dec 2015
Raltegravir (Isentress®) for children (1113/15)	For treatment of human immunodeficiency virus (HIV-1) infection in children from the age of 4 weeks to <2 years	Formulary - Hospital use (HIV Paediatrics)	<a href="#">152</a>	Nov/Dec 2015
Raltegravir (Isentress®) (902/13)	Patients who are intolerant or resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs)	HOSPITAL ONLY Paediatrics under supervision of HIV specialists in Glasgow and Edinburgh	<a href="#">130</a>	Sept/Oct 2013
Raltegravir (Isentress®) (613/10)	HIV-1 infection	HOSPITAL ONLY (HIV Clinic)	<a href="#">96</a> <a href="#">79</a>	Apr/May 2010 May 2008
Ramucirumab 10 mg/ml concentrate for solution for infusion (Cyramza®) SMC2291	In combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.		<a href="#">185</a>	July 2021
Ramucirumab 10mg/mL concentrate for solution for infusion (Cyramza®) SMC2246	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of $\geq 400$ ng/mL and who have been previously treated with sorafenib		<a href="#">178</a>	Feb 2020
Ramucirumab (Cyramza®) 1176/16	In combination with paclitaxel for the treatment of adults patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.  As monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.	Not available as not recommended for use in NHS Scotland	<a href="#">156</a>	Sep 2016

Ramicurinab 10mg concentrate for solution for infusion (Cymaza®) SMC 1156/16	In combination with FOLFIRI (irinocetan, folinic acid and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaloplatin and a fluoropyrimidine	Not available as not recommended for use in NHS Scotland	<a href="#">155</a>	June 2016
Ranibizumab 10mg/mL solution for injection / 10mg/mL solution for injection in pre-filled syringe (Lucentis®) SMC 2270	Is not recommended for use within NHSScotland. Treatment of proliferative diabetic retinopathy in adults.	For information only	<a href="#">180</a>	Sept 2020
Ranibizumab (Lucentis®) (907/13)	Treatment for visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults.	HOSPITAL ONLY (Ophthalmology)	<a href="#">132</a>	Nov/Dec 2013
Ranibizumab (Lucentis®) (711/11)	Treatment of visual impairment due to diabetic macular oedema (DMO) in adults.	HOSPITAL ONLY (Ophthalmology)	<a href="#">124</a> <a href="#">123</a>	Feb 2013 Jan 2013
Ranibizumab (Lucentis®) (732/11)	For the treatment of visual impairment due to macular oedema (MO) secondary to retinal vein occlusion (RVO) (branch RVO or central RVO) in adults.	HOSPITAL ONLY	<a href="#">127</a> <a href="#">112</a> <a href="#">109</a>	May 2013 Dec 2011 Sept 2011
Ranibizumab (Lucentis®) (381/07)	Treatment of neovascular (wet) age-related macular degeneration (AMD)	HOSPITAL ONLY (Ophthalmology Clinic)	<a href="#">69</a>	June 2007
Ranolazine (Ranexa®) (565/09)	Stable angina Pectopris	Not recommended	<a href="#">122</a> <a href="#">114</a> <a href="#">101</a>  <a href="#">92</a>	Dec 2012 Feb 2012 Dec 10/Jan 2011 Aug/Sept 2009
Rasagiline (Azilect®)	Idiopathic Parkinson's disease as monotherapy	Not recommended	<a href="#">64</a> <a href="#">56</a>	2006
Rasagiline (Azilect®)	Idiopathic Parkinson's disease as adjunct therapy	Not recommended	<a href="#">64</a>	2006

	Parkinson's disease		<a href="#">56</a>	
Ravulizumab (Ultomiris) SMC2330	For the treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab. SMC restriction: under the advice of the national renal complement therapeutics service Two single-arm, phase III studies demonstrated the beneficial treatment effect of ravulizumab on complete thrombotic microangiopathy (TMA) response, defined as normalisation of haematological parameters and improvement in renal function.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">185</a>	July 2021
Ravulizumab 300mg concentrate for solution for infusion (Ultomiris®) SMC2305	For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): • In patients with haemolysis with clinical symptom(s) indicative of high disease activity • In patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. SMC restriction: under the advice of the national PNH service	Available in line with local guidance for prescribing	<a href="#">183</a>	March 2021
Ravulizumab concentrate for solution for infusion (Ultomiris®) SMC2657	As an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.		197 – Awaiting publication	Apr 2024
Ravulizumab concentrate for solution for infusion (Ultomiris®) SMC2658	Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody positive.		197 – Awaiting publication	Apr 2024
Recombinant E.coli asparaginase 10,000 units	As a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric	Not routinely available as local clinical experts do not	<a href="#">168</a>	May 2018

powder for concentrate for solution for infusion (Spectrila®) SMC No 1319/18	<p>patients from birth to 18 years and adults.</p> <p>Asparaginase produced in E. coli cells has been used in NHS Scotland as an unlicensed medicine as part of treatment of ALL in children and adults; asparaginase (Spectrila®) provides a licensed alternative.</p>	wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines		
regorafenib film-coated tablets (Stivarga) SMC2562	as monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.	Available in line with national guidance	<a href="#">195</a>	December 2023
Regorafenib 40mg film-coated tablets (Stivarga®) SMC No 1316/18	As monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib.	Available in line with national guidance	<a href="#">169</a>	July 2018
Regorafenib (Stivarga®) (1118/15)	Adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies.	Not recommended	<a href="#">152</a>	Nov/Dec 2015
Regorafenib (Stivarga®) (1031/15)	Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib	<p>Non-Formulary - Absence of clinician demand</p> <p>Supplied via a patient access scheme</p>	<a href="#">147</a>	Apr 2015
Relugolix 40mg, estradiol 1mg, norethisterone acetate 0.5mg film-coated tablets (Ryeqo®) SMC2442	<p>Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.</p> <p>SMC restriction: for use in patients who have failed or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine delivery systems.</p> <p>Relugolix, estradiol, norethisterone acetate tablets (Ryeqo®),</p>	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">190</a>	August 2022

	compared with placebo, significantly reduced menstrual blood loss volume in patients with uterine fibroids and heavy menstrual bleeding.			
Remimazolam 20mg powder for solution for injection (Byfavo®) SMC2454	In adults for procedural sedation. In three randomised, multicentre, phase III studies, remimazolam treatment resulted in a significantly higher rate of procedure success in patients undergoing colonoscopy or bronchoscopy when compared with placebo.	Not available as not recommended for use in NHS Scotland	<a href="#">190</a>	August 2022
Retapamulin (Altargo®) (472/08)	Impetigo and infected small wounds	Not recommended	<a href="#">78</a>	Apr 2008
Retigabine (Trobalt®) (712/11)	Adjunctive treatment of partial onset seizures	GPs may prescribe under the direction of the Neurology Clinic	<a href="#">111</a> <a href="#">109</a>	Nov 2011 Sept 2011
Reslizumab 10mg/mL concentrate for solution for infusion (Cinqaero®) SMC No 1233/17	As add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.	Not available as not recommended for use in NHS Scotland	<a href="#">166</a>	Feb 2018
Ribociclib 200mg film-coated tablets (Kisqali®) SMC2198	For the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy, or in women who have received prior endocrine therapy. SMC restriction: women who have relapsed on or within 12 months of completing (neo) adjuvant endocrine therapy, or those who have progressed on first-line endocrine-based therapy for advanced breast cancer.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">178</a>	Feb 2020
Ribociclib 200mg film-coated tablets (Kisqali®) SMC No 1295/18	In combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.	Available in line with national guidance	<a href="#">168</a>	May 2018

Ritlecitinib hard capsules (Litfulo) SMC 2610	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In a randomised, double-blind, phase IIb/III study in patients with severe alopecia areata, ritlecitinib was associated with statistically significant improvements in scalp hair regrowth versus placebo at week 24		197	May 2024
Rifampicin (Voractiv®) (876/13)	Initial treatment of tuberculosis	Not recommended	<a href="#">127</a>	May 2013
Rifaximin (Targaxan®) (893/13)	Reduction in recurrence of episodes of overt hepatic encephalopathy (HE) > 18 years of age	GPs under the direction of Gastroenterology	<a href="#">130</a>	Sept/Oct 2013
Rifaximin (Xifaxanta®) (806/12)	Travellers' diarrhoea	Not recommended	<a href="#">119</a>	Aug/Sept 2012
Rilpivirine/emtricitabine/tenofovir alafenamide 200mg/25mg/25mg film-coated tablets (Odefsey®) SMC 1189/16	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.	Available in line with national guidance	<a href="#">158</a>	Dec 2016
Rilpivirine 25mg film-coated tablet (Edurant®)	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV1) infection in antiretroviral treatment naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/ml	Available from a specialist Centre in another Board	<a href="#">156</a>	Sep 2016
Rilpivirine (Edurant®) (758/12)	HIV-1	HOSPITAL ONLY (HIV Clinic)	<a href="#">115</a>	Mar/Apr 2012
Rimegepant oral lyophilisate (Vydura®) SMC2603	For the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.  SMC restriction: for patients with episodic migraine who have at least 4 migraine attacks per month, but fewer than 15 headache days per month and who have had prior failure on three or more migraine preventive treatments	Not routinely available as local implementation plans are being developed	<a href="#">195</a>	December 2023

Rimegepant oral lyophilisate (Vydura®) SMC2521	For the acute treatment of migraine with or without aura in adults.  SMC restriction: for patients who have had inadequate symptom relief after trials of at least two triptans or in whom triptans are contraindicated or not tolerated; and have inadequate pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">193</a>	June 2023
Rimegepant oral lyophilisate (Vydura®) SMC2567	For the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.	Not available as not recommended for use in NHS Scotland	<a href="#">193</a>	June 2023
Rimonabant (Acomplia®)	Obesity in patients with risk factors	Not recommended	<a href="#">66</a>	Feb 2007
Riociguat (Adempas®)  (1056/15)	Pulmonary arterial hypertension (PAH): as monotherapy or in combination with endothelin receptor antagonists, for the treatment of adult patients with PAH with World Health Organisation Functional Class (WHO FC) II to III to improve exercise capacity.	HOSPITAL ONLY  (Under the direction of the Scottish Pulmonary Vascular Centres)	<a href="#">150</a>	June 2015
Riociguat (Adempas®) (1001/14)	CTEPH	Non-formulary - restricted to the Scottish Pulmonary Vascular Unit (tertiary referral)	<a href="#">144</a>	Jan/Feb 2015
Risankizumab 600mg concentrate for solution for infusion and 360mg solution for injection (Skyrizi®) SMC2534	For the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.	PAEDS Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for	<a href="#">195</a>	Dec 2023



		alternative medicines.		
Risankizumab 150mg solution for injection in a pre-filled syringe or pen (Skyrizi®) SMC2459	Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). SMC restriction: (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy (biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional DMARDs and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Risankizumab 75mg solution for injection in pre-filled syringe (Skyrizi®) SMC2196	For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Available in line with local guidance for prescribing	<a href="#">177</a>	Dec 2019
risdiplam 0.75mg/mL powder for oral solution (Evrysdi®) SMC2401	for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies. Evidence from two phase II/III studies has indicated that risdiplam improves motor milestones and motor function in patients with type 1, 2 and 3 SMA.	ADULT SERVICES - Available in line with local guidance PAEDIATRICS - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">188</a>	April 2022
Risedronate (Actonel®) (424/07)	Osteoporosis in men	Not recommended	<a href="#">75</a>	Dec 2007
Risedronate (Actonel® once a week)	Osteoporosis in postmenopausal women		<a href="#">26</a>	2003

Risperidone depot (Risperdal Consta®)	Schizophrenia	HOSPITAL ONLY (Mental Health specialist list)	<a href="#">23 Protocol</a>	2002
Risperidone (Risperdal®)	Mania in bipolar disorder		<a href="#">43</a>	2004
Risperidone (Risperdal Quicklet®) (403/07)	Schizophrenia, bipolar disorder		<a href="#">72</a>	Sept 2007
Rituximab 100mg Concentrate for Solution for Infusion (MabThera®) SMC2193	Treatment of patients with moderate to severe pemphigus vulgaris.	Not available as not recommended for use in NHS Scotland	<a href="#">175</a>	Aug 2019
Rituximab 100mg, 500mg solution for infusion (MabThera®) SMC2165	In combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).	Not available as not recommended for use in NHS Scotland	<a href="#">174</a>	May 2019
Rituximab (MabThera®) (975/14)	Non-Hodgkin's lymphoma (NHL) in adults	HOSPITAL ONLY (Haematology)	<a href="#">140</a>	Jul/Aug 2014
Rituximab (MabThera®) (894/13)	Adults with severe, active granulomatosis with polyangitis (Wegener's) (GPA) and MPA	HOSPITAL ONLY	<a href="#">131</a> <a href="#">130</a>	Oct/Nov 2013 Sept/Oct 2013
Rituximab (MabThera®) (591/09)	Chronic lymphocytic leukaemia (CLL)	HOSPITAL ONLY (Haematology)	<a href="#">108 Protocol</a> <a href="#">94</a> <a href="#">90</a>	Aug 2011 Dec 09/Jan 10 June 2009
Rituximab (MabThera®)	CD20 +ve large B-cell NHL		<a href="#">25</a>	2003
Rituximab (MabThera®) (493/08)	First-line treatment of stage III-IV follicular lymphoma	HOSPITAL ONLY	<a href="#">82</a> <a href="#">47</a>	Aug/Sept 2008 2004
Rituximab (MabThera®)	Severe active rheumatoid arthritis (RA)	HOSPITAL ONLY (Rheumatology Clinic)	<a href="#">72 Protocol</a>	Sept 2007

			<a href="#">63</a>	2006
Rituximab (MabThera®) (675/11)	Maintenance therapy for follicular lymphoma responding to induction	HOSPITAL ONLY (Haematology)	<a href="#">118</a> <a href="#">103</a>	July 2012 Feb/Mar 2011
Rituximab (MabThera®)	Maintenance therapy for relapsed/refractory follicular lymphoma		<a href="#">64</a>	2006
Rivaroxaban 2.5mg film-coated tablet (Xarelto®) SMC2128	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery disease at high risk of ischaemic events. SMC restriction: use in patients with stable coronary artery disease that does not require dual antiplatelet therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">174</a>	May 2019
Rivaroxaban (Xarelto®) (1062/15)	Rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.	Not recommended	<a href="#">150</a>	June 2015
Rivaroxaban (Xarelto®) (775/12)	DVT	Formulary - first line Note: A dose reduction is no longer required if eGFR is 30-49mls/min for treatment of PE/DVT only. See Supplement No <a href="#">127</a> May 2013	<a href="#">115</a>	Mar/Apr 2012
Rivaroxaban (Xarelto®) (852/13)	Pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults	Formulary - first line	<a href="#">128</a> (update) <a href="#">126</a>	June/July 2013 Apr 2013
Rivaroxaban (Xarelto®) (756/12)	Prevention of stroke and systemic embolism in adults	Formulary - first line new oral anticoagulant Note: A dose reduction is no	<a href="#">115</a>	Mar/Apr 2012

		longer required if eGFR is 30-49mls/min for treatment of PE/DVT only. See Supplement No <a href="#">127</a> May 2013		
Rivaroxaban (Xarelto®) (519/08)	VTE in adults	HOSPITAL ONLY (Orthopaedics)	<a href="#">86</a> <a href="#">Protocol</a> <a href="#">85</a>	Dec 2008
Rivastigmine transdermal patch (Exelon®)	Moderately severe Alzheimer's dementia		<a href="#">97</a> <a href="#">75</a>	June/July 2010 Dec 2007
Rivastigmine (Exelon®)	Mild to moderately severe dementia in patients with Parkinson's disease.	Not recommended	<a href="#">60</a>	2006
Roflumilast, 500 microgram, film-coated tablet (Daxas®) SMC No. (635/10)	For maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1]) post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.	Not available as not recommended for use in NHS Scotland	<a href="#">100</a> <a href="#">164</a>	Oct 2017
Rolapitant (as hydrochloride monohydrate) 90mg film-coated tablets (Varuby®) SMC No. (1266/17)	Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy	Available in line with national guidance	<a href="#">164</a>	Oct 2017
Romiplostim 125 micrograms, 250 micrograms, 500 micrograms powder for solution for injection (Nplate®) SMC2126	Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). SMC restriction: to use in patients with severe symptomatic ITP or patients with a high risk of bleeding.	Available from a specialist centre in another NHS Board	<a href="#">174</a>	May 2019
Romiplostim (Nplate®) (553/09)	Idiopathic Thrombocytopenic purpura (ITP)	HOSPITAL ONLY Non-formulary (Haematology)	<a href="#">93</a>	Oct/Nov 2009

Romosozumab 105mg solution for injection in pre-filled pen (Evenity®) SMC2280	Treatment of severe osteoporosis in postmenopausal women at high risk of fracture. SMC restriction: to use in patients who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months).	Available in line with local guidance for prescribing	<a href="#">182</a>	January 2021
Ropeginterferon alfa-2b solution for injection in pre-filled pen (Besremi®) SMC2563	As monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	Not available as not recommended for use in NHS Scotland	<a href="#">194</a>	September 2023
Ropeginterferon alfa-2b 250 micrograms/0.5 ml solution for injection in pre-filled pen (Besremi®) SMC2421 AOP Orphan Ltd	As monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.  In a phase III study, ropeginterferon alfa-2b failed to demonstrate non-inferiority to hydroxycarbamide in treatment-naïve patients who required cytoreductive therapy and in patients who had a partial response to hydroxycarbamide.		<a href="#">189</a>	May 2022
Ropinirole (Requip® XL®) (491/08)	Idiopathic Parkinson's disease	Non-formulary	<a href="#">82</a>	Aug/Sept 2008
Ropinirole (Adartrel®)	Moderate to severe idiopathic restless legs syndrome (RLS)	Formulary	<a href="#">60</a> <a href="#">151</a>	2006 2015
Rosiglitazone (Avandia®)  Discontinued November 2010	Triple therapy in type 2 diabetes	Discontinued	<a href="#">98</a> <a href="#">52</a>	Aug/Sept 2010 2005
Rosiglitazone (Avandia®)  Discontinued November 2010	Type 2 diabetes mellitus (monotherapy)	Discontinued	<a href="#">98</a> <a href="#">75</a> <a href="#">67</a> <a href="#">43</a> <a href="#">37</a>	Aug/Sept 2010 Dec 2007 Mar 2007 2004

Rosiglitazone/metformin (Avandamet®) Discontinued November 2010	Triple therapy in type 2 diabetes	Discontinued	<a href="#">98</a> <a href="#">67</a> <a href="#">60</a>	Aug/Sept 2010 Mar 2007 2006
Rosiglitazone/metformin (Avandamet®) Discontinued November 2010	Type 2 diabetes mellitus	Discontinued	<a href="#">98</a> <a href="#">61</a> <a href="#">49</a> <a href="#">47</a> <a href="#">39</a> <a href="#">37</a>	Aug/Sept 2010 2006  2004
Rosuvastatin (Crestor®) (725/11)	Lipid lowering	Not recommended	<a href="#">111</a> <a href="#">89</a> <a href="#">26</a>	Nov 2011 2009 2003
Rotigotine 1mg, 2mg and 3mg per 24 hours transdermal patch (Neupro®) (548/09)	Symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults	Formulary	<a href="#">94</a> <a href="#">92</a>  <a href="#">151</a>	Dec 09/Jan 10 Aug/Sep 09 Sep/Oct 15
Rotigotine transdermal patch (Neupro®)	Advanced Parkinson's disease in combination with levodopa		<a href="#">81</a> <a href="#">72</a>	July 2008 Sept 2007
Rotigotine transdermal patch (Neupro®)	Early-stage idiopathic Parkinson's disease		<a href="#">81</a> <a href="#">71</a> <a href="#">60</a>	July 2008 July 2007 2006
Ropeginterferon alfa-2b solution for injection in pre-filled pen (Besremi®) SMC2563	As monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	Not available as not recommended for use in NHS Scotland	<a href="#">194</a>	September 2023
Roxadustat 20mg, 50mg, 70mg,	Treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).	Not routinely available as local	<a href="#">190</a>	August 2022

100mg and 150mg film-coated tablets (Evrenzo®) SMC2461	SMC restriction: for use in patients who are non-dialysis dependent (NDD) at the time of treatment initiation. Roxadustat was non-inferior to an erythropoiesis stimulating agent (ESA) and superior to placebo for improving haemoglobin (Hb) levels in adults with anaemia in CKD who were NDD.	clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Rucaparib 200mg, 250mg, 300mg film-coated tablets (Rubraca®) SMC 2224	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. SMC restriction: to patients who do not have a BRCA mutation	Available in line with national guidance	<a href="#">180</a>	Sept 2020
Rucaparib 200mg, 250mg and 300mg film-coated tablets (Rubraca®) SMC2221	As monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.	Not available as not recommended for use in NHS Scotland	<a href="#">176</a>	Oct 2019
Rufinamide 40mg/mL oral suspension and 100mg, 200mg, 400mg tablets (Inovelon®) SMC2146	As adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to ≤4 years. SMC restriction: restricted to use in patients who have failed treatment with or are intolerant of other antiepileptic drugs	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">174</a>	May 2019
Rufinamide (Inovelon®) (795/12)	Adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome	GPs under the direction of the Paediatric Neurology Clinic	<a href="#">119</a> <a href="#">152</a>	Aug 2012 Nov/Dec 2015
Rufinamide (Inovelon®) (416/07)	Seizures associated with Lennox-Gastaut syndrome	GPs under the direction of the Paediatric Neurology Clinic	<a href="#">84</a> <a href="#">74</a> <a href="#">152</a>	Nov 2008 Nov 2007 Nov/Dec 2015

Rupatadine (Rupafin®) (612/10)	Allergic rhinitis and chronic idiopathic urticaria	Not recommended	<a href="#">95</a>	Feb/Mar 2010
Ruxolitinib cream (Opzelura®) SMC2634	For the treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.	Not recommended	197	Awaiting publication
Ruxolitinib 5mg, 10mg, 15mg and 20mg tablets (Jakavi®) SMC2498	For the treatment of: <ul style="list-style-type: none"> <li>• patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids</li> <li>• patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids</li> </ul>	Not available as not recommended for use in NHS Scotland	<a href="#">190</a>	August 2022
Ruxolitinib phosphate 5mg, 10mg, 15mg, 20mg tablets (Jakavi®) SMC2213	The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide).	Available in line with local guidance for prescribing	<a href="#">178</a>	Feb 2020
Ruxolitinib (Jakavi®) (867/13)	Disease-related splenomegaly	Not recommended	<a href="#">127</a>	May 2013
Ruxolitinib (as phosphate) (Jakavi®) (867/13)	The treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.	HOSPITAL ONLY - (Haematology)  Supplied via a Patient Access Scheme	<a href="#">146</a>	Mar 2015

Updated: 15<sup>th</sup> March 2024

[Back to top](#)

[Back to homepage](#)